




The relative strengths and weaknesses of Nexvet Biopharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nexvet Biopharma plc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 132% points. The greatest weakness of Nexvet Biopharma plc is the variable Other Revenues, reducing the Economic Capital Ratio by 7.6% points.

The company's Economic Capital Ratio, given in the ranking table, is 398%, being 135% points above the market average of 263%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	55,941	Assets	56,672
Cost of Goods Sold	0	Liabilities	3,094
Intangible Assets	19	Expenses	20,036
Liabilities, Current	3,033	Revenues	3,960
Liabilities, Non-Current	61	Stockholders Equity	53,578
Other Assets	163	Net Income	-11,857
Other Compr. Net Income	-4,920	Comprehensive Net Income	-14,317
Other Expenses	0	BaseVar	46,450
Other Liabilities	0	ECR before LimitedLiability	343%
Other Net Income	4,219	Economic Capital Ratio	398%
Other Revenues	3,960		
Property and Equipment	549		
Research and Development	9,845		
Selling, General and Administrative Expense	10,191		